Oncology Drug Reference Sheet: Combination Trastuzumab and Hyaluronidase-Oysk
Chelsea Backler MSN, APRN, AGCNS-BC, AOCNS®, VA-BC
Voice
Description
A new product that combines trastuzumab and hyaluronidase (Herceptin Hylecta™) received U.S. Food and Drug Administration (FDA) approval in February 2019 for the treatment of HER2-overexpressing breast cancer. The approval was based on the results of two randomized trials: HannaH and SafeHER.
ONS Drug Education
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education